Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

WuXi AppTec merges two service divisions

by Rick Mullin
August 7, 2017 | A version of this story appeared in Volume 95, Issue 32

Chinese pharmaceutical services firm WuXi AppTec will merge its contract manufacturing division, STA Pharmaceutical, with its finished-dose drug business, WuXi AppTec Pharmaceutical Development Services. The firm says the move will enable STA to advance chemical entities from preclinical stages to the filing of New Drug Applications and commercial manufacturing more efficiently than by operating separate units. The merger is in keeping with a trend to establish end-to-end contracting services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.